1Department of Internal Medicine, Seoul St. Mary's Hospital, Seoul, Korea.
2Department of Pathology, Seoul St. Mary's Hospital, Seoul, Korea.
3Department of Surgery, Seoul St. Mary's Hospital, Seoul, Korea.
4Department of Internal Medicine, Uijeongbu St. Mary's Hospital, Uijeongbu, Korea.
5Department of Internal Medicine, St. Vincent's Hospital, Suwon, The Catholic University of College of Medicine, Korea.
Copyright © 2013 by the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Characteristic | No. (%) |
---|---|
Median age (range, yr) | 61 (36-80) |
Gender (male/female) | 69/35 |
Diagnosis | |
ICC | 17 (16.3) |
HC | 41 (39.4) |
EHC | 46 (44.2) |
Lymph node | |
N0 | 67 (64.4) |
N1 | 37 (35.6) |
Stage | |
I | 38 (36.5) |
II | 46 (44.2) |
III | 20 (19.2) |
Adjuvant treatmenta) | |
Yes | 53 (51.0) |
No | 48 (46.2) |
Recurrence | |
Yes | 61 (58.7) |
No | 33 (31.7) |
Not availableb) | 7 (7.6) |
Lymphatic invasion | Venous invasion | Perineural invasion | |
---|---|---|---|
ICC | 4 (23.5) | 3 (17.6) | 4 (23.5) |
HC | 14 (34.1) | 5 (12.2) | 35 (85.4) |
EHC | 15 (32.6) | 4 (8.7) | 30 (65.2) |
p-value | 0.721 | 0.606 | <0.001 |
Characteristic | No. (%) |
---|---|
Median age (range, yr) | 61 (36-80) |
Gender (male/female) | 69/35 |
Diagnosis | |
ICC | 17 (16.3) |
HC | 41 (39.4) |
EHC | 46 (44.2) |
Lymph node | |
N0 | 67 (64.4) |
N1 | 37 (35.6) |
Stage | |
I | 38 (36.5) |
II | 46 (44.2) |
III | 20 (19.2) |
Adjuvant treatment |
|
Yes | 53 (51.0) |
No | 48 (46.2) |
Recurrence | |
Yes | 61 (58.7) |
No | 33 (31.7) |
Not available |
7 (7.6) |
Lymphatic invasion | Venous invasion | Perineural invasion | |
---|---|---|---|
ICC | 4 (23.5) | 3 (17.6) | 4 (23.5) |
HC | 14 (34.1) | 5 (12.2) | 35 (85.4) |
EHC | 15 (32.6) | 4 (8.7) | 30 (65.2) |
p-value | 0.721 | 0.606 | <0.001 |
p53 | TP | ERCC1 | Survivin | Cyclin D1 | |
---|---|---|---|---|---|
ICC | 6 (46.2) | 8 (61.5) | 5 (38.2) | 3 (23.1) | 2 (15.4) |
HC | 18 (47.4) | 25 (65.8) | 9 (23.7) | 14 (36.8) | 8 (21.1) |
EHC | 19 (52.8) | 17 (47.2) | 12 (34.3) | 170 (47.2) | 9 (25.0) |
p-value | 0.869 | 0.258 | 0.115 | 0.289 | 0.763 |
Prognostic factor | ICC |
HC |
EHC |
|||
---|---|---|---|---|---|---|
n | p-value | n | p-value | n | p-value | |
Lymph node involvement | ||||||
+ | 7.2 | 0.005 | 20.8 | NS | 19.4 | NS |
– | 34 | 24.5 | 23.3 | |||
Adjuvant therapy | ||||||
Yes | 21.8 | 0.028 | 32.0 | 0.021 | 30.8 | 0.004 |
No | 14.5 | 20.6 | 16.8 | |||
Differentiation | ||||||
Well | 15.0 | NS | 36.2 | 0.05 | 31.1 | 0.004 |
Moderate | 21.8 | 19.9 | 16.8 | |||
Poor | 14.5 | 6.2 | 11.4 | |||
Lymphatic invasion | ||||||
+ | 7.1 | 0.001 | 17.7 | NS | 18.3 | NS |
– | 31.2 | 24.5 | 24.0 | |||
Venous invasion | ||||||
+ | 7.2 | 0.031 | 15.2 | NS | 16.4 | NS |
– | 21.8 | 24.5 | 21.9 | |||
Perineural invasion | ||||||
+ | 13.4 | NS | 19.9 | NS | 18.6 | NS |
– | 20.5 | 20.8 | 20.8 | |||
p53 | ||||||
+ | 14.5 | NS | 29.9 | NS | 21.9 | NS |
– | 18.1 | 31.3 | 16.8 | |||
TP | ||||||
+ | 12.5 | NS | 28.3 | NS | 18.9 | 0.037 |
– | 18.3 | 25.2 | 24.0 | |||
ERCC1 | ||||||
+ | 15.5 | NS | 10.5 | 0.029 | 12.4 | 0.05 |
– | 20.1 | 32.0 | 23.3 | |||
Survivin | ||||||
+ | 13.4 | NS | 25.9 | NS | 22.4 | NS |
– | 15.9 | 32.0 | 23.5 | |||
Cyclin D1 | ||||||
+ | 31.2 | NS | 32.0 | NS | 21.5 | NS |
– | 18.1 | 29.9 | 21.9 |
ICC, intrahepatic cholangiocarcinoma; HC, hilar cholangiocarcinoma; EHC, extrahepatic cholangiocarcinoma.
a)Three patients who underwent R2 resection were excluded, b)Seven patients were lost to follow up.
Values are presented as number (%). ICC, intrahepatic cholangiocarcinoma; HC, hilar cholangiocarcinoma; EHC, extrahepatic cholangiocarcinoma.
Values are presented as number (%).TP, thymidine phosphorylase; ERCC1, excision repair cross-complementing group 1; ICC, intrahepatic cholangiocarcinoma; HC, hilar cholangiocarcinoma; EHC, extrahepatic cholangiocarcinoma.
ICC, intrahepatic cholangiocarcinoma; HC, hilar cholangiocarcinoma; EHC, extrahepatic cholangiocarcinoma; NS, not significant; TP, thymidine phosphorylase; ERCC1, excision repair cross-complementing group 1.